Novo Nordisk launches high-dose Wegovy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk has launched a high-dose version of Wegovy, signaling an escalation in the obesity drug market.
- Insurers are experiencing successes within Medicare Advantage, as reported by The Readout, indicating shifts in healthcare coverage.
- The obesity drug race continues to be a significant area of competition and innovation in the biotech news landscape.
Why it matters: Novo Nordisk's high-dose Wegovy launch directly impacts the competitive landscape for obesity treatments.
